Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890680666> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2890680666 endingPage "299" @default.
- W2890680666 startingPage "294" @default.
- W2890680666 abstract "A sub-analysis of a Phase III study was conducted to identify factors that might predict increased ferritin levels during long-term sucroferric oxyhydroxide (SO) treatment in hemodialysis patients.The open-label, multicenter, Phase III study assessed the efficacy and safety of SO 750-3000 mg/day for 52 weeks in Japanese patients with chronic renal failure and hyperphosphatemia. A total of 125 of 161 patients from the Phase III trial, and who had data for ferritin levels after 28 weeks of SO treatment, were evaluated.Baseline ferritin was the strongest contributor (P < 0.0001) to ferritin increases during SO treatment. By Week 28, there were significant differences (P < 0.05/3) in ferritin increases between patients with higher [quartile 4 (Q4)] versus lower (Q1, Q2 and Q3) baseline ferritin. An erythropoiesis-stimulating agent dosage reduction was observed in patients with the lowest baseline ferritin level (Q1), and only slight reductions were noted in the other patient subsets. SO dosages administered to patients in baseline ferritin quartiles Q2, Q3 and Q4 were comparable throughout the study with slight fluctuations. SO dosages in Q1 were considerably lower than those in the other quartiles.In summary, of the baseline variables found to predict increased ferritin, and changes in iron-related parameters, during SO treatment in Japanese chronic kidney disease patients undergoing hemodialysis, baseline ferritin was the most relevant variable." @default.
- W2890680666 created "2018-09-27" @default.
- W2890680666 creator A5053498181 @default.
- W2890680666 creator A5071555943 @default.
- W2890680666 creator A5074986055 @default.
- W2890680666 creator A5089711554 @default.
- W2890680666 date "2018-09-19" @default.
- W2890680666 modified "2023-09-23" @default.
- W2890680666 title "Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment" @default.
- W2890680666 cites W2010528248 @default.
- W2890680666 cites W2037543291 @default.
- W2890680666 cites W2056694775 @default.
- W2890680666 cites W2069868276 @default.
- W2890680666 cites W2095421717 @default.
- W2890680666 cites W2110177967 @default.
- W2890680666 cites W2117116215 @default.
- W2890680666 cites W2117639138 @default.
- W2890680666 cites W2120202209 @default.
- W2890680666 cites W2164481110 @default.
- W2890680666 cites W2313433516 @default.
- W2890680666 cites W2419119266 @default.
- W2890680666 cites W2465834252 @default.
- W2890680666 cites W2569327376 @default.
- W2890680666 cites W2580449060 @default.
- W2890680666 cites W2619181830 @default.
- W2890680666 doi "https://doi.org/10.1093/ckj/sfy077" @default.
- W2890680666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6452212" @default.
- W2890680666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30976411" @default.
- W2890680666 hasPublicationYear "2018" @default.
- W2890680666 type Work @default.
- W2890680666 sameAs 2890680666 @default.
- W2890680666 citedByCount "2" @default.
- W2890680666 countsByYear W28906806662019 @default.
- W2890680666 countsByYear W28906806662022 @default.
- W2890680666 crossrefType "journal-article" @default.
- W2890680666 hasAuthorship W2890680666A5053498181 @default.
- W2890680666 hasAuthorship W2890680666A5071555943 @default.
- W2890680666 hasAuthorship W2890680666A5074986055 @default.
- W2890680666 hasAuthorship W2890680666A5089711554 @default.
- W2890680666 hasBestOaLocation W28906806661 @default.
- W2890680666 hasConcept C126322002 @default.
- W2890680666 hasConcept C162156334 @default.
- W2890680666 hasConcept C2776036575 @default.
- W2890680666 hasConcept C2778063415 @default.
- W2890680666 hasConcept C2778319317 @default.
- W2890680666 hasConcept C2778653478 @default.
- W2890680666 hasConcept C44249647 @default.
- W2890680666 hasConcept C68443243 @default.
- W2890680666 hasConcept C71924100 @default.
- W2890680666 hasConcept C90924648 @default.
- W2890680666 hasConceptScore W2890680666C126322002 @default.
- W2890680666 hasConceptScore W2890680666C162156334 @default.
- W2890680666 hasConceptScore W2890680666C2776036575 @default.
- W2890680666 hasConceptScore W2890680666C2778063415 @default.
- W2890680666 hasConceptScore W2890680666C2778319317 @default.
- W2890680666 hasConceptScore W2890680666C2778653478 @default.
- W2890680666 hasConceptScore W2890680666C44249647 @default.
- W2890680666 hasConceptScore W2890680666C68443243 @default.
- W2890680666 hasConceptScore W2890680666C71924100 @default.
- W2890680666 hasConceptScore W2890680666C90924648 @default.
- W2890680666 hasIssue "2" @default.
- W2890680666 hasLocation W28906806661 @default.
- W2890680666 hasLocation W28906806662 @default.
- W2890680666 hasLocation W28906806663 @default.
- W2890680666 hasOpenAccess W2890680666 @default.
- W2890680666 hasPrimaryLocation W28906806661 @default.
- W2890680666 hasRelatedWork W1975678811 @default.
- W2890680666 hasRelatedWork W2017642851 @default.
- W2890680666 hasRelatedWork W2087336177 @default.
- W2890680666 hasRelatedWork W2349377538 @default.
- W2890680666 hasRelatedWork W2392489645 @default.
- W2890680666 hasRelatedWork W2612412937 @default.
- W2890680666 hasRelatedWork W2890680666 @default.
- W2890680666 hasRelatedWork W3215440883 @default.
- W2890680666 hasRelatedWork W4213188781 @default.
- W2890680666 hasRelatedWork W4252372221 @default.
- W2890680666 hasVolume "12" @default.
- W2890680666 isParatext "false" @default.
- W2890680666 isRetracted "false" @default.
- W2890680666 magId "2890680666" @default.
- W2890680666 workType "article" @default.